Cargando…

Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile

Aim: Design and synthesis of thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors.Material and methods: A series of novel 6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]pyrimidine derivatives with different substituents on C-4 position was synthesized and evaluated for their anticance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mghwary, Aml E.-S., Gedawy, Ehab M., Kamal, Aliaa M., Abuel-Maaty, Suzan M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442109/ https://www.ncbi.nlm.nih.gov/pubmed/30919701 http://dx.doi.org/10.1080/14756366.2019.1593160

Ejemplares similares

Design, synthesis, anticancer evaluation, and molecular modelling studies of novel tolmetin derivatives as potential VEGFR-2 inhibitors and apoptosis inducers
por: Kassab, Asmaa E., et al.
Publicado: (2021)

Novel Anticancer Fused Pyrazole Derivatives as EGFR and VEGFR-2 Dual TK Inhibitors
por: Saleh, Nashwa M., et al.
Publicado: (2020)

In Silico Screening and Anticancer-Apoptotic Evaluation of Newly Synthesized Thienopyrimidine/Sulfonamide Hybrids
por: Elmongy, Elshaymaa I., et al.
Publicado: (2023)

Synthesis of Novel Biocompatible Thienopyrimidine Chromophores with Aggregation-Induced Emission Sensitive to Molecular Aggregation
por: Ahmed, Mostafa, et al.
Publicado: (2020)

Click chemistry based synthesis, cytotoxic activity and molecular docking of novel triazole-thienopyrimidine hybrid glycosides targeting EGFR
por: Khattab, Reham R., et al.
Publicado: (2021)

Synthesis, Anticancer Assessment, and Molecular Docking of Novel Chalcone-Thienopyrimidine Derivatives in HepG2 and MCF-7 Cell Lines
por: Safwat, Ghada M., et al.
Publicado: (2021)

Design, synthesis, and biological evaluation of novel ciprofloxacin derivatives as potential anticancer agents targeting topoisomerase II enzyme
por: Swedan, Hadeer K., et al.
Publicado: (2022)

Design, Synthesis, and Biological Evaluation of Novel Thienopyrimidine Derivatives as PI3Kα Inhibitors
por: Yu, Lide, et al.
Publicado: (2019)

Synthesis and biological evaluation of novel thienopyrimidine derivatives as diacylglycerol acyltransferase 1 (DGAT-1) inhibitors
por: Hong, Dong Jin, et al.
Publicado: (2019)

Design, synthesis, in silico docking, ADMET and anticancer evaluations of thiazolidine-2,4-diones bearing heterocyclic rings as dual VEGFR-2/EGFR(T790M) tyrosine kinase inhibitors
por: Aziz, Nada A. A. M., et al.
Publicado: (2022)

Synthesis, Anticancer Screening of Some Novel Trimethoxy Quinazolines and VEGFR2, EGFR Tyrosine Kinase Inhibitors Assay; Molecular Docking Studies
por: Altamimi, Abdulmalik S., et al.
Publicado: (2021)

Synthesis and bioevaluation of thienopyrimidines bearing a pyrazoline unit as selective PI3Kα inhibitors
por: Lai, Luogen, et al.
Publicado: (2019)

Novel Thienopyrimidine Inhibitors of Leishmania N-Myristoyltransferase with On-Target Activity in Intracellular Amastigotes
por: Bell, Andrew S., et al.
Publicado: (2020)

Design and synthesis of novel cytotoxic fluoroquinolone analogs through topoisomerase inhibition, cell cycle arrest, and apoptosis
por: Elanany, Mohamed A., et al.
Publicado: (2023)

Thienopyrimidine: A Promising Scaffold to Access Anti-Infective Agents
por: Lagardère, Prisca, et al.
Publicado: (2021)

Identification of Novel Cyanopyridones and Pyrido[2,3-d]pyrimidines as Anticancer Agents with Dual VEGFR-2/HER-2 Inhibitory Action: Synthesis, Biological Evaluation and Molecular Docking Studies
por: Al-Warhi, Tarfah, et al.
Publicado: (2022)

Fragment merging approach for design, synthesis, and biological assessment of urea/acetyl hydrazide clubbed thienopyrimidine derivatives as GSK-3β inhibitors
por: Saleh, Joseph S., et al.
Publicado: (2023)

Five and six membered heterocyclic rings endowed with azobenzene as dual EGFR(T790M) and VEGFR-2 inhibitors: design, synthesis, in silico ADMET profile, molecular docking, dynamic simulation and anticancer evaluations
por: Anwer, Kurls E., et al.
Publicado: (2023)

Molecular design, synthesis and in vitro biological evaluation of thienopyrimidine–hydroxamic acids as chimeric kinase HDAC inhibitors: a challenging approach to combat cancer
por: Abdel-Atty, Mona M., et al.
Publicado: (2021)

In Vitro Anticancer Activity Screening of Novel Fused Thiophene Derivatives as VEGFR-2/AKT Dual Inhibitors and Apoptosis Inducers
por: Abdelnaby, Rana M., et al.
Publicado: (2022)

Design and Discovery of Quinazoline- and Thiourea-Containing Sorafenib Analogs as EGFR and VEGFR-2 Dual TK Inhibitors
por: Sun, Shaofeng, et al.
Publicado: (2017)

New benzothiazole hybrids as potential VEGFR-2 inhibitors: design, synthesis, anticancer evaluation, and in silico study
por: Al-Sanea, Mohammad M., et al.
Publicado: (2023)

Thienopyrimidine Derivatives as GPR55 Receptor Antagonists: Insight into Structure–Activity Relationship
por: Figuerola-Asencio, Laura, et al.
Publicado: (2022)

Synthesis, anticancer, apoptosis-inducing activities and EGFR and VEGFR2 assay mechanistic studies of 5,5-diphenylimidazolidine-2,4-dione derivatives: Molecular docking studies
por: Alkahtani, Hamad M., et al.
Publicado: (2019)

EGFR and COX-2 Dual Inhibitor: The Design, Synthesis, and Biological Evaluation of Novel Chalcones
por: Musa, Arafa, et al.
Publicado: (2022)

Novel Thienopyrimidine-Based PET Tracers for P2Y(12) Receptor Imaging in the Brain
por: van der Wildt, Berend, et al.
Publicado: (2021)

Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2
por: Yousef, Reda G., et al.
Publicado: (2022)

Wnt-pathway inhibitors with selective activity against triple-negative breast cancer: From thienopyrimidine to quinazoline inhibitors
por: Boudou, Cédric, et al.
Publicado: (2022)

Design, Synthesis, Molecular Modeling, and Anticancer Evaluation of New VEGFR-2 Inhibitors Based on the Indolin-2-One Scaffold
por: Abdelgawad, Mohamed A., et al.
Publicado: (2022)

Synthesis and Anticancer Activities of Pyrazole–Thiadiazole-Based EGFR Inhibitors
por: Kurban, Berkant, et al.
Publicado: (2023)

Association between EGFR/KRAS mutation and expression of VEGFA, VEGFR and VEGFR2 in lung adenocarcinoma
por: Yuan, Xiao-Han, et al.
Publicado: (2018)

New Thiazolyl-Pyrazoline Derivatives as Potential Dual EGFR/HER2 Inhibitors: Design, Synthesis, Anticancer Activity Evaluation and In Silico Study
por: Fakhry, Mariam M., et al.
Publicado: (2023)

Correction to Novel Thienopyrimidine-Based PET Tracers for P2Y(12) Receptor Imaging in the Brain
por: van der Wildt, Berend, et al.
Publicado: (2022)

Discovery of novel thiazolyl-pyrazolines as dual EGFR and VEGFR-2 inhibitors endowed with in vitro antitumor activity towards non-small lung cancer
por: Abdelsalam, Esraa A., et al.
Publicado: (2022)

Vitamin D Enhances Anticancer Properties of Cediranib, a VEGFR Inhibitor, by Modulation of VEGFR2 Expression in Melanoma Cells
por: Piotrowska, Anna, et al.
Publicado: (2021)

Erratum: Wnt-pathway inhibitors with selective activity against triple-negative breast cancer: From thienopyrimidine to quinazoline inhibitors
por: Frontiers Production Office,
Publicado: (2023)

Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2
por: Sangande, Frangky, et al.
Publicado: (2020)

New Anticancer Theobromine Derivative Targeting EGFR(WT) and EGFR(T790M): Design, Semi-Synthesis, In Silico, and In Vitro Anticancer Studies
por: Elkaeed, Eslam B., et al.
Publicado: (2022)

Design and synthesis of phthalazine-based compounds as potent anticancer agents with potential antiangiogenic activity via VEGFR-2 inhibition
por: Elmeligie, Salwa, et al.
Publicado: (2019)

Discovery of sulfonamide-tethered isatin derivatives as novel anticancer agents and VEGFR-2 inhibitors
por: Shaldam, Moataz A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kun7f9cg31jrokqodplqagnqeb